Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

Clinical trials aiming to develop disease-altering drugs for Alzheimer’s disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Declercq, Lieven D., Vandenberghe, Rik, Van Laere, Koen, Verbruggen, Alfons, Bormans, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814730/
https://www.ncbi.nlm.nih.gov/pubmed/27065872
http://dx.doi.org/10.3389/fphar.2016.00088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814730/
https://www.ncbi.nlm.nih.gov/pubmed/27065872
http://dx.doi.org/10.3389/fphar.2016.00088

Ejemplares similares